Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Glaxo Withdraws Raxar Following Seven Fatal Cardiovascular AEs

Executive Summary

Glaxo Wellcome is withdrawing the quinolone antibiotic Raxar (grepafloxacin) from the worldwide markets after receiving a total of seven reports of cardiovascular event-related fatalities associated with use of the drug.

You may also be interested in...



GSK/Otsuka settle Raxar dispute

GlaxoSmithKline agrees to make payment to Otsuka to settle the companies' dispute over 1999 withdrawal of the antibiotic Raxar. Otsuka initiated arbitration proceedings in December 2001, arguing that the withdrawal constituted material breach of contract. Glaxo withdrew Raxar due to cardiovascular safety concerns (1"The Pink Sheet" Nov. 1, 1999, p. 17)...

GSK/Otsuka settle Raxar dispute

GlaxoSmithKline agrees to make payment to Otsuka to settle the companies' dispute over 1999 withdrawal of the antibiotic Raxar. Otsuka initiated arbitration proceedings in December 2001, arguing that the withdrawal constituted material breach of contract. Glaxo withdrew Raxar due to cardiovascular safety concerns (1"The Pink Sheet" Nov. 1, 1999, p. 17)...

Bayer Avelox Skin Infection Indication "Approvable"; Needs More Safety Data

Bayer's Avelox (moxifloxacin) is "approvable" for the treatment of uncomplicated skin and skin structure infections, FDA said in a Dec. 10 letter granting the antibiotic approval for three other indications.

UsernamePublicRestriction

Register

PS035083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel